Related Experiment Video

Updated: Jun 19, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Effects of vitamin D3 (cholecalciferol) on adriamycin-induced nephrotoxicity

Durrin Ozlem Dabak1, Tuncay Kuloglu, Mehmet Resat Ozercan

  • 1Firat University Medical School, Departments of Histology and Embryology, Elazig, Turkey. dozlemdabak@firat.edu.tr

Renal Failure
|October 21, 2009
PubMed

Insights

Vitamin D(3) (cholecalciferol) shows promise in mitigating adriamycin (ADR)-induced kidney damage. This study found cholecalciferol significantly reduced tubular lesions and aided recovery in rats with ADR nephrotoxicity.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Adriamycin (ADR) is known to cause nephrotoxicity, with immune-mediated pathogenesis increasingly recognized.
  • Limited research exists on the therapeutic potential of immunomodulators, like vitamin D, in counteracting ADR-induced kidney damage.

Purpose of the Study:

  • To investigate the protective effects of vitamin D(3) (cholecalciferol) on adriamycin-induced nephropathy in a rat model.
  • To evaluate the immunomodulatory impact of cholecalciferol on ADR-induced kidney toxicity.

Main Methods:

  • Eighteen male Wistar rats were divided into control, ADR-induced nephropathy, and ADR + cholecalciferol groups.
  • ADR was administered intravenously; cholecalciferol was given orally daily for 21 days.
  • Urinary protein:creatinine ratio and kidney tissue histology were analyzed.

Main Results:

  • ADR injection led to a significant increase in urinary protein:creatinine ratio in both ADR-treated groups compared to controls.
  • Histological analysis revealed severe tubular lesions (necrosis, degeneration, casts) in ADR-treated rats.
  • Cholecalciferol administration significantly reduced the severity of these tubular lesions compared to ADR alone.

Conclusions:

  • Vitamin D(3) (cholecalciferol) demonstrates significant tubulointerstitial recovery effects in ADR-induced nephrotoxicity.
  • These findings suggest cholecalciferol's potential as a therapeutic agent for ADR nephrotoxicity due to its immunomodulatory properties.

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...